FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588735087> ?p ?o ?g. }

• W2588735087 abstract "Abstract Background. Mitoxantrone is an anthracenedione derivative with cytostatic and immunomodulatory activity, which is licensed for worsening multiple sclerosis (MS), an autoimmune central nervous system disease. The occurrence of acute promyelocytic leukaemia (APL) following mitoxantrone therapy in MS has been sporadically reported, but its actual incidence and clinical outcome need further definition Aims and Methods. Among 1050 patients with a diagnosis of MS followed at our Institution since 1985, the clinical records of those receiving mitoxantrone were reviewed, in order to clarify the incidence of secondary APL as well as its clinical characteristics and outcome. Results. Since 1990, 98 patients affected by MS were treated with mitoxantrone, in most cases as third-line treatment after corticosteroids and interferon therapy. Four patients (M/F: 1/4) developed APL. Median age at presentation was 57.5 year (range 47–59), significantly higher than that of unselected MS patients. APL developed a median of 55.5 months (range 3766 mo) after the first course of mitoxantrone. The median total dose of mitoxantrone was 149 mg (range 35–234 mg), delivered over a median of 7 courses (3–13). The cumulative number of years of follow-up after the start of mitoxantrone was 690. Therefore the risk of developing APL in this cohort was 5.8‰. All but one patients were classified as low-risk APL according to the GIMEMA/PETHEMA scoring system, the fourth being intermediate-risk. Morphology was FAB M3v in 1 case, and classic in the remaining. Typical chromosomal translocation t(15;17) was observed in all patients as well as PML/RAR-α molecular rearrangement, of bcr1 type in all. Flt-3 mutation was always absent. Given the treatment-related pathogenesis of APL, a modification of the AIDA2000 treatment program was used, with a reduced dose of idarubicin during induction in 2 patients. The second consolidation course with mitoxantrone was avoided by repeating the first course twice. Complete hematologic and cytogenetic remission was obtained after induction in all patients. Two patients are receiving consolidation. Molecular response was documented after consolidation in the other two patients. Both of them relapsed. The first had molecular relapse after 4 months; he was treated with ATRA and Ara-C and obtained a second molecular remission, lasting 50+ months. The second patient showed a morphological relapse after 5 months. She was treated with arsenic trioxide obtaining a second complete morphologic and molecular remission, but relapsed 1 month after autologous peripheral stem cell transplantation given for consolidation. She is currently on reinduction therapy with arsenic trioxide, 26 months after diagnosis. Conclusions. APL is a rare hematological disease, but its incidence among mitoxantrone-treated MS patients is significantly increased, like in patients with malignant diseases treated with mitoxantrone. Age is a major risk factor for the development of mitoxantrone-related APL. Analysis of further potential risk-factor is ongoing. The clinical outcome of this subset of patients seems worse than in de-novo APL. The use of anthracyclines as part of the treatment program needs further evaluation." @default.
• W2588735087 created "2017-02-24" @default.
• W2588735087 creator A5020086659 @default.
• W2588735087 creator A5026990551 @default.
• W2588735087 creator A5028460878 @default.
• W2588735087 creator A5034123305 @default.
• W2588735087 creator A5038394370 @default.
• W2588735087 creator A5038660271 @default.
• W2588735087 creator A5041794776 @default.
• W2588735087 creator A5057157458 @default.
• W2588735087 creator A5059985491 @default.
• W2588735087 creator A5083744505 @default.
• W2588735087 creator A5084419421 @default.
• W2588735087 date "2006-11-16" @default.
• W2588735087 modified "2023-09-26" @default.
• W2588735087 title "An Analysis of the Incidence, Risk Factors and Prognosis of Acute Promyelocytic Leukemia Following Mitoxantrone Therapy in Patients Affected by Multiple Sclerosis." @default.
• W2588735087 doi "https://doi.org/10.1182/blood.v108.11.4488.4488" @default.
• W2588735087 hasPublicationYear "2006" @default.
• W2588735087 type Work @default.
• W2588735087 sameAs 2588735087 @default.
• W2588735087 citedByCount "0" @default.
• W2588735087 crossrefType "journal-article" @default.
• W2588735087 hasAuthorship W2588735087A5020086659 @default.
• W2588735087 hasAuthorship W2588735087A5026990551 @default.
• W2588735087 hasAuthorship W2588735087A5028460878 @default.
• W2588735087 hasAuthorship W2588735087A5034123305 @default.
• W2588735087 hasAuthorship W2588735087A5038394370 @default.
• W2588735087 hasAuthorship W2588735087A5038660271 @default.
• W2588735087 hasAuthorship W2588735087A5041794776 @default.
• W2588735087 hasAuthorship W2588735087A5057157458 @default.
• W2588735087 hasAuthorship W2588735087A5059985491 @default.
• W2588735087 hasAuthorship W2588735087A5083744505 @default.
• W2588735087 hasAuthorship W2588735087A5084419421 @default.
• W2588735087 hasConcept C120665830 @default.
• W2588735087 hasConcept C121332964 @default.
• W2588735087 hasConcept C126322002 @default.
• W2588735087 hasConcept C141071460 @default.
• W2588735087 hasConcept C143998085 @default.
• W2588735087 hasConcept C151032500 @default.
• W2588735087 hasConcept C203014093 @default.
• W2588735087 hasConcept C2776694085 @default.
• W2588735087 hasConcept C2780640218 @default.
• W2588735087 hasConcept C2780923524 @default.
• W2588735087 hasConcept C61511704 @default.
• W2588735087 hasConcept C71924100 @default.
• W2588735087 hasConcept C72563966 @default.
• W2588735087 hasConcept C88879693 @default.
• W2588735087 hasConcept C90924648 @default.
• W2588735087 hasConceptScore W2588735087C120665830 @default.
• W2588735087 hasConceptScore W2588735087C121332964 @default.
• W2588735087 hasConceptScore W2588735087C126322002 @default.
• W2588735087 hasConceptScore W2588735087C141071460 @default.
• W2588735087 hasConceptScore W2588735087C143998085 @default.
• W2588735087 hasConceptScore W2588735087C151032500 @default.
• W2588735087 hasConceptScore W2588735087C203014093 @default.
• W2588735087 hasConceptScore W2588735087C2776694085 @default.
• W2588735087 hasConceptScore W2588735087C2780640218 @default.
• W2588735087 hasConceptScore W2588735087C2780923524 @default.
• W2588735087 hasConceptScore W2588735087C61511704 @default.
• W2588735087 hasConceptScore W2588735087C71924100 @default.
• W2588735087 hasConceptScore W2588735087C72563966 @default.
• W2588735087 hasConceptScore W2588735087C88879693 @default.
• W2588735087 hasConceptScore W2588735087C90924648 @default.
• W2588735087 hasLocation W25887350871 @default.
• W2588735087 hasOpenAccess W2588735087 @default.
• W2588735087 hasPrimaryLocation W25887350871 @default.
• W2588735087 hasRelatedWork W2023240648 @default.
• W2588735087 hasRelatedWork W2023475282 @default.
• W2588735087 hasRelatedWork W2044063690 @default.
• W2588735087 hasRelatedWork W2062576060 @default.
• W2588735087 hasRelatedWork W2095337546 @default.
• W2588735087 hasRelatedWork W2114461289 @default.
• W2588735087 hasRelatedWork W2403498931 @default.
• W2588735087 hasRelatedWork W2415666441 @default.
• W2588735087 hasRelatedWork W2419486628 @default.
• W2588735087 hasRelatedWork W2971763932 @default.
• W2588735087 isParatext "false" @default.
• W2588735087 isRetracted "false" @default.
• W2588735087 magId "2588735087" @default.
• W2588735087 workType "article" @default.